ArticleArquivos brasileiros de cardiologia2022
Septal Ablation with Radiofrequency Catheters Guided by Echocardiography for Treatment of Patients with Obstructive Hypertrophic Cardiomyopathy: Initial Experience.
Article in Arquivos brasileiros de cardiologia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 11 citations in OpenAlex.
- Efficacy and safety of radiofrequency ablation for hypertrophic obstructive cardiomyopathy: a meta-analysis.Future cardiology · 2025Pooled it
- Guidelines on the Diagnosis and Treatment of Hypertrophic Cardiomyopathy - 2024.Arquivos brasileiros de cardiologia · 2024Guideline
- Multimodality echocardiography in structural heart disease: the evolving role of the interventional imager.European heart journal. Imaging methods and practice · 2026Review
- Percutaneous endocardial septal radiofrequency ablation in patients with hypertrophic obstructive cardiomyopathy.BMC cardiovascular disorders · 2025Article
- Septal Preparation for TAVR Using Radiofrequency Catheters in Patients With LVOT Obstruction: 1-Year Follow-Up.JACC. Case reports · 2025Article
- Efficacy and safety of myectomy and radiofrequency septal ablation for treating hypertrophic obstructive cardiomyopathy.Open heart · 2025Observational
- Radiofrequency Ablation for Patients with Hypertrophic Obstructive Cardiomyopathy Accompanied by Severe Left Ventricular Outflow Tract Obstruction.Anatolian journal of cardiology · 2024Article
- Percutaneous endocardial septal radiofrequency ablation on syncope in patients with hypertrophic obstructive cardiomyopathy: a short-term safety and efficacy study.Annals of medicine and surgery (2012) · 2024Article
- A Narrative Review of Emerging Therapies for Hypertrophic Obstructive Cardiomyopathy.Current cardiology reviews · 2023Review
- Septal Ablation with Radiofrequency and the Use of New Technologies in Patients with Hypertrophic Cardiomyopathy in an Electrophysiology LaboratoryReply.Arquivos brasileiros de cardiologia · 2022Article
- Echocardiography Guiding Percutaneous Treatment of Obstructive Hypertrophic Cardiomyopathy: Navigating (In Known Waters) Is Necessary.Arquivos brasileiros de cardiologia · 2022Article
- Effect of Perioperative Comprehensive Nursing Intervention on the Rehabilitation Effect of Radiofrequency Ablation for Patients with Hypertrophic Obstructive Cardiomyopathy.Contrast media & molecular imaging · 2022Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypertrophic cardiomyopathy (HCM) can cause obstruction in the left ventricular outflow tract (LVOT), and be responsible for the onset of limiting symptoms, such as tiredness. When such symptoms are refractory to pharmacological treatment, interventionist alternative therapies can be useful, such as septal ablation through the infusion of alcohol in the coronary artery or through myectomy. Recently, the use of a radiofrequency (RF) catheter for endocardial septal ablation guided by electroanatomic mapping has proven to be efficient, despite the high incidence of complete atrioventricular block. An alternative would be the application of RF at the beginning point of the septal gradient guided by the transesophageal echocardiography (TEE). The echocardiography is an imaging method with high accuracy to determine septal anatomy.
objectiveTo assess the long term effect of septal ablation for the relief of ventricular-arterial gradient, using TEE to help place the catheter in the area of larger septal obstruction. Besides, to assess the effects of ablation on the functional class and echocardiographic parameters.
methodsTwelve asymptomatic patients, with LVOT obstruction, refractory to pharmacological therapy, underwent endocardial septal ablation with 8mm-tip catheters, whose placement was oriented in the region of larger obstruction, assisted by the TEE. Temperature-controlled and staggered RF applications were performed. After each application, the gradient was reassessed and a new application was performed according to the clinical criterion. The effects of RF applications were assessed both for the gradient at rest and for that provoked by the Valsalva maneuver, and considering the gradient. The differences were significant when p-value was lower than or equal to 0.05.
resultsIt was possible to observe that the mean reduction of the maximum gradients was from 96.8±34.7 mmHg to 62.7±25.4 mmHg three months after the procedure (p=0.0036). After one year, the mean of maximum gradient was 36.1±23.8 mmHg (p=0.0001). The procedure was well tolerated, without records of complete atrioventricular block nor severe complications.
conclusionThe TEE-guided septal ablation was efficient and safe, and the results were maintained during the clinical follow-up period. It is a reasonable option for the interventionist treatment of LVOT obstruction in HCM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.